| Drug Name | enfuvirtide |
|---|---|
| Other Drug Names | T20; DP178 |
| Chemical Name | acetyl-L-tyrosyl-L-threonyl-L-seryl-L-leucyl-L-isoleucyl-L-histidyl-L-seryl- L-leucyl-L-isoleucyl-L-α-glutamyl-L-α-glutamyl-L-seryl-L-glutaminyl- L-asparaginyl-L-glutaminyl-L-glutaminyl-L-α-glutamyl-L-lysyl-L-asparaginyl- L--glutamyl-L-glutaminyl-L-α-glutamyl-L-leucyl-L-leucyl-L-α-glutamyl-L-leucyl- L-α-aspartyl-L-lysyl-L-tryptophyl-L-alanyl-L-seryl-L-leucyl-L-tryptophyl- L-asparaginyl-L-tryptophyl-L-phenylalaninamide |
| Formula | C204H301N51O64 |
| Mol. Wt. | 4491.9149 |
| CAS No. | 159519-65-0 |
| UNII | 19OWO1T3ZE |
| Target-based Actions | HIV gp41 protein modulator |
| ATC Codes | J05AX07 |
| Highest Status | 2003年批准上市 |
| Originator Company | Trimeris, Inc.; Roche Colorado Corp. |
| Structure |
 |
Extended Information